Amycretin (Zenagamtide)
Also known as: Zenagamtide
Amycretin combines GLP-1 and amylin receptor activation in a single investigational molecule. Early oral and injectable studies show weight-loss signals, with major questions about durability and tolerability still open.
Quick Facts
Identity and formulations
Novo Nordisk is developing amycretin, also called zenagamtide, for weight management. One molecule activates both GLP-1 and amylin receptors. The development program includes a once-weekly subcutaneous formulation and a once-daily oral formulation; neither is an approved treatment.
Sources: [1]
Appetite and metabolic mechanisms
The GLP-1 component increases insulin secretion when glucose is elevated, slows gastric emptying and reduces appetite. Its incretin target is shared with medicines such as semaglutide. The amylin component acts on another pancreatic-hormone pathway involved in fullness.
Combining these satiety signals may reduce food intake more than either pathway alone. That is the development rationale, while clinical studies must establish the extent and persistence of benefit.
Development and product status
Amycretin is not approved by the FDA or another regulator in the published account. Novo Nordisk reports advancement of both oral and injectable formulations into Phase 3 weight-management development. AMAZE 1 began recruiting in February 2026; a recruiting Phase 3 program is not a positive Phase 3 efficacy result.
Sources: [4]
Human findings and tolerability
The published human evidence remains early phase:
| Study | Duration | Findings and limits |
|---|---|---|
| Subcutaneous Phase 1b/2a, reported in 2025 | Up to 36 weeks; 125 adults with overweight or obesity | Weight loss increased with dose. At 36 weeks, the 60 mg arm lost 24.3% versus 1.1% with placebo; p < 0.0001. Gastrointestinal adverse events were mostly mild or moderate, but withdrawal/discontinuation was notably high. |
| First-in-human oral study | 12 weeks | Primary emphasis was safety and drug exposure; weight-change observations were exploratory. |
These small, short trials do not establish long-term efficacy or tolerability, and no Phase 3 efficacy findings are described in these reports. The 60 mg figure is a study-arm dose rather than an approved prescribing schedule.
Sources: [5]
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1016/S0140-6736(26)01247-XIdentity and formulationsCited in: Identity and formulations
- ncbi.nlm.nih.govAppetite and metabolic mechanismsCited in: Appetite and metabolic mechanisms
- 10.1016/S0140-6736(25)01185-7Appetite and metabolic mechanismsCited in: Appetite and metabolic mechanisms
- clinicaltrials.govDevelopment and product statusCited in: Development and product status
- 10.1016/S0140-6736(25)01176-6Human findings and tolerabilityCited in: Human findings and tolerability
Frequently Asked Questions About Amycretin (Zenagamtide)
Related Peptides
Continue exploring Amycretin (Zenagamtide)
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.